ENLV

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing therapies to reprogram immune cells for treatment of life-threatening conditions. The company's lead product candidate, Allocetra, is an off-the-shelf cell therapy designed to restore immune system balance in patients with severe conditions like sepsis and acute respiratory distress syndrome. Enlivex's approach involves using early apoptotic cells to modulate the immune response. The company is conducting clinical trials in multiple indications including COVID-19 complications.